Back to today’s briefing

Story perspectives

TAXIS Pharmaceuticals Wins $2.9M Grant to Fight Super Gonorrhea

7/15/2025

26 2

Summary

Story summary

TAXIS Pharmaceuticals has secured a $2.9 million grant from the National Institute of Allergy and Infectious Diseases to combat the rising threat of super gonorrhea. With a focus on developing dihydrofolate reductase inhibitors, the company is advancing its promising investigational drug TXA 15054, which could be a game-changer in the fight against this dangerous strain.

1 of 1

Story summary

TAXIS Pharmaceuticals has secured a $2.9 million grant from the National Institute of Allergy and Infectious Diseases to combat the rising threat of super gonorrhea. With a focus on developing dihydrofolate reductase inhibitors, the company is advancing its promising investigational drug TXA 15054, which could be a game-changer in the fight against this dangerous strain.